Opinion

Podcast

Widening the Therapeutic Window in the Management of Parkinson’s Disease

Author(s):

Stuart H. Isaacson, MD, FAAN,Rajesh Pahwa, MD

Expert neurologists discuss strategies to widen the therapeutic window of Parkinson’s disease and options available to treat dyskinesia, providing better control of Parkinson’s disease.

To watch the full video episode, follow this link.

1:12 Long-term challenges

4:00 Levodopa fluctuations

6:30 Therapeutic window

9:20 Amantadine DR/ER for PD

11:30 Dyskinesia treatment

18:10 Amantadine candidates

23:34 PK of amantadine

27:15 Early treatment

Related Videos
Related Content
Parkinson Agent HL192 Successfully Completes Phase 1 First-In-Human Study
November 26th 2024

Parkinson Agent HL192 Successfully Completes Phase 1 First-In-Human Study

Marco Meglio
Multisymptomatic Care in Parkinson's Disease
September 4th 2024

Multisymptomatic Care in Parkinson's Disease

Stuart H. Isaacson, MD, FAAN Rajesh Pahwa, MD Jennifer G. Goldman, MD, MS
StrivePD: Revolutionizing Parkinson Disease Care Through Data and Personalization
November 23rd 2024

StrivePD: Revolutionizing Parkinson Disease Care Through Data and Personalization

Marco Meglio
Sleeping Around the Podcast × NeurologyLive: Candidate Biomarkers to Detect REM Sleep Behavior Disorder in Parkinson Disease
April 9th 2024

Sleeping Around the Podcast × NeurologyLive: Candidate Biomarkers to Detect REM Sleep Behavior Disorder in Parkinson Disease

Anne Marie Morse, DO, FAASM NeurologyLive® Staff
Triheptanoin Shows No Significant Effect on Movement Disorder Events in Glut1 Deficiency Syndrome
November 20th 2024

Triheptanoin Shows No Significant Effect on Movement Disorder Events in Glut1 Deficiency Syndrome

Marco Meglio
Phase 3 ARISE Trial of Parkinson Therapy Solengepras Begins Dosing
November 19th 2024

Phase 3 ARISE Trial of Parkinson Therapy Solengepras Begins Dosing

Marco Meglio
© 2024 MJH Life Sciences

All rights reserved.